1. Corporate presentation January 2013

2. What we do

3. In depth technical expertise

4. Ithaka Track Record >190 assignments completed for >90 clients Worked with >25 universities on technology commercialisation 9 university spin-outs created and financed >£30 million funding for clients o Venture capital, corporate deals and grants Technical, commercial & IP evaluations undertaken for >30 organisations Due diligence conducted for 9 investment funds Unrivalled network of contacts

5. Ithaka Team Paul Rodgers Founder & MD, experienced biotech entrepreneur, biomarkers & personalised medicine AxisJohn Adair Biopharmaceutical R&D (Axis Genetics, Scotgen, Celltech, Searle) Richard Cumming Life science product development & marketing (Amersham, GE Healthcare) Bill Primrose Drug discovery & development (PanTherix, SioKem etc.) Mark Treherne Drug discovery & development (Senexis, Cyclofluidic, BioFocus, Pfizer etc.) Paula Wittels Medical devices & diagnostics (Pfizer, Quintiles etc.)

6. Ithaka: University Clients

7. Ithaka: Corporate Clients creating a new cancer therapy

8. Typical Assignments Business creation & sourcing finance  Psynova Neurotech & Smart Holograms Technical, commercial and market evaluation  Newcastle University: biofilm prevention  Manchester University: novel medical implant device  Scottish Enterprise: medical device, anaesthesia  University of Bath: human and animal vaccine technology Due diligence  Apposite (Anaphore), Finance Wales (ADCB) & Wellcome (Kymab) Strategic advice  ThermoFisher, Smith & Nephew, Wellcome Genome Campus Management, mentoring & coaching  ProteinLogic, Scottish Enterprise & Theryte Portfolio review  Bloomsbury Bioseed Fund

9. Case Study: Psynova Neurotech Biomarkers for psychiatric disorders –Potential applications in diagnostics, drug discovery and development Ithaka role –Development of commercial strategy, business plan & securing of finance in 2007 –Paul Rodgers: chairman from 2007 to 2012 Results –University spin-out company 2007 –> £8M investment & grant funding –First diagnostic product launched in 2010 –Commercial deal with Roche Pharmaceuticals Dec 2009 –Acquired by Myriad Genetics 2011

10. Why Work with Ithaka? Personal experience –Technology commercialisation –New ventures –Fund raising –Growth through strategic partnerships –Across the life science spectrum Multi-disciplinary team approach Unique network of contacts Support tailored to meet the client’s needs